PMLiVE6d
J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study
Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...
PMLiVE5d
PMLiVE’s T40 – results announced!
The 2024 edition of PMLiVE’s T40 list of creative agencies working on advertising, branding, creative and design projects in ...
PMLiVE11d
Top-10 ways for Pharma to leverage AI according to…AI
Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s ...
PMLiVE5d
Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults
Ipsen’s Iqirvo (elafibranor) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat ...
PMLiVE13d
FDA approves IntraBio’s Aqneursa to treat Niemann-Pick disease type C patients
The US Food and Drug Administration (FDA) has approved IntraBio’s Aqneursa (levacetylleucine) to treat neurological symptoms ...
PMLiVE12d
Roche’s Genentech acquires Regor Pharmaceuticals’ CDK inhibitors for $850m upfront
One of the candidates included in the deal has already shown promise in a phase 1a advanced breast cancer study ...
PMLiVE4d
Merck’s Keytruda shows promise as perioperative head and neck cancer treatment
Keytruda works by increasing the ability of the body’s immune system to help detect and fight tumour cells, and is already approved as a monotherapy and in combination regimens for certain patients ...
PMLiVE14d
Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension
Johnson & Johnson’s (J&J) Yuvanci (single tablet combination therapy [STCT] of macitentan and tadalafi) has been approved by the European Commission (EC) as a long-term treatment for pulmonary ...
PMLiVE5d
GSK’s RSV vaccine Arexvy shown to protect older adults across three seasons
GSK’s Arexvy has been shown to protect older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) over three full RSV seasons. Results from the phase 3 ...
PMLiVE13d
Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...
PMLiVE13d
Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis
Bristol Myers Squibb (BMS) has announced positive results from a phase 3b/4 study of its oral TYK2 inhibitor Sotyktu (deucravacitinib) in moderate-to-severe scalp psoriasis. Data from the ongoing ...
PMLiVE12d
Results from Global Pharmaceutical Customer Experience survey
Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...